Extended Data Fig. 5: Clinical progression and neoantigen quantity and quality.
From: A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
a, DFS of patients that recurred. b, CT image before and after of a patient with recurrent metastatic disease. c, Neoantigen load based on predicted binding (predicted kD of < 500 nM and mutant kD <wild-type kD). d, Number of high-quality neoantigens that are likely to be recognized by TCRs based on neoantigen fitness model42 at post-treatment versus recurrence time points.
